Source comparison
The Growth Hormone Axis — MK-677 vs Direct IGF Administration
MK-677 (ibutamoren) functions as a selective ghrelin receptor agonist. It mimics the hunger hormone ghrelin's binding to GHSR1a receptors in the anterior pituitary, stimulating growth hormone secretion in distinct pulses that mirror physiological GH release pa
This comparison does not assign a generated winner or score.
- MK-677 (ibutamoren) functions as a selective ghrelin receptor agonist. It mimics the hunger hormone ghrelin's binding to GHSR1a receptors in the anterior pituitary, stimulating growth hormone secretion in distinct pulses that mirror physiological GH release patterns. A 1997 clinical trial published in the Journal of Clinical Endocrinology & Metabolism demonstrated that 25mg daily MK-677 increased serum IGF-1 levels by 89% and growth hormone secretion by 97% over baseline in healthy young adults. The half-life is approximately 24 hours, meaning once-daily oral administration maintains stable receptor occupancy.
- IGF-1 LR3 (Long R3 IGF-1) is a recombinant analog of human IGF-1 with an arginine substitution at position 3 and a 13-amino-acid N-terminal extension. These structural modifications reduce binding affinity to IGF-binding proteins (IGFBPs) by approximately 100-fold compared to native IGF-1. The result is a circulating half-life of 20–30 hours versus 12–15 hours for endogenous IGF-1, and significantly enhanced tissue bioavailability because the peptide remains unbound and receptor-active rather than sequestered by carrier proteins. Research protocols exploit this extended activity window for localized anabolic effects that MK-677's systemic GH elevation cannot replicate.
- The mechanistic difference shapes protocol design: MK-677 elevates baseline IGF-1 systemically over weeks, creating an anabolic environment that affects all IGF-responsive tissues. IGF-1 LR3 delivers acute, high-concentration receptor activation in specific target tissues within hours of administration. Researchers combining both compounds are layering chronic systemic upregulation with acute localized signaling. The rationale is sound, but the execution depends on timing precision and peptide integrity most standard protocols ignore.